Who makes Alfilbercept?

Alfilbercept is developed by Vitreous -Retina- Macula Consultants of New York.

What development phase is Alfilbercept in?

Alfilbercept is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Alfilbercept

Vitreous -Retina- Macula Consultants of New York · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Alfilbercept
Sponsor	Vitreous -Retina- Macula Consultants of New York
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD (PHASE4)
Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alfilbercept CI brief — competitive landscape report
Alfilbercept updates RSS · CI watch RSS
Vitreous -Retina- Macula Consultants of New York portfolio CI